Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care

0.75 CME
0.75 COPE
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care


Release date: August 10, 2021
Expiration date: August 10, 2022
Estimated time to complete: 0.75 hour

Provider Statement

Jointly provided by


Activity Description

The past two decades have seen the development of numerous new targeted therapies for multiple myeloma (MM). Included among these are antibody–drug conjugates (ADCs), which have shown significant promise in improving patient prognoses but are associated with unique adverse events (AEs). In particular, ADCs containing monomethyl auristatin F (MMAF) have been linked to increased incidence of corneal epithelial changes. With the FDA’s 2020 approval of belantamab mafodotin (the first ADC indicated for MM treatment)—and its accompanying risk evaluation and mitigation strategy (REMS)—the issues of managing potential ocular toxicity and conducting routine ophthalmologic monitoring throughout the course of treatment become paramount.

This activity has been developed to provide ophthalmologists and optometrists involved in the care of MM patients receiving belantamab mafodotin guidance on the recommended management strategies for immunotherapy-associated ocular AEs.

Target Audience

This activity has been designed to meet the educational needs of ophthalmologists, optometrists, and other eye care specialists involved in the care of patients with MM who are receiving belantamab mafodotin therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the symptoms and severity of corneal microcyst-like epithelial changes occurring as a result of ADC use in patients with MM
  • Provide the recommended ophthalmologic monitoring of patients on ADCs to prevent treatment complications


Ajay K. Nooka, MD, MPH, FACP
Associate Professor
Department of Hematology and Medical Oncology
Medical Director, Winship Research Informatics Shared Resource
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Praneetha Thulasi, MD
Assistant Professor of Ophthalmology
Emory Eye Center
Atlanta, Georgia 

Joint Accreditation Statement

Jointly Accredited ProviderIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RedMedEd. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Council on Optometric Practitioner Education (COPE)

Postgraduate Institute for Medicine is accredited by COPE to provide continuing education to optometrists.

Credit Statement: This course is COPE approved for 0.75 hour of CE credit. Activity #121668 and Course ID 72458-GO. Check with your local state licensing board to see if this counts toward your CE requirement for re-licensure.

Reviewed by Salus 


Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Ajay K. Nooka, MD, MPH, FACP, has disclosed the following relevant financial relationships:

Consulting Fees: Adaptive, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi, Takeda

Praneetha Thulasi, MD, has disclosed the following relevant financial relationships:

Panel Discussion: GlaxoSmithKline, PeerView Institute

The PIM planners and others have nothing to disclose. The RedMedEd planners and others have nothing to disclose.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for this activity, participants must complete the posttest (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately.

Contact Information

For information about the accreditation of this program, please contact inquiries@pimed.com.

For technical questions related to this activity or issues with your CME certificate, please contact RedMedEd at 610.251.6841 or education@redmeded.com.


CME credit for this activity is provided by the Postgraduate Institute for Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the Postgraduate Institute for Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through the Postgraduate Institute for Medicine or RedMedEd. For more information, contact inquiries@pimed.com or education@redmeded.com.


© 2021. This CME-certified program is held as copyrighted by the Postgraduate Institute for Medicine and RedMedEd. Through this notice, the Postgraduate Institute for Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.